Skip to contentX
Xenon Pharmaceuticals Inc.
X
XENEXenon Pharmaceuticals Inc. Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$0.00$0.00derivedno prior Q4 2023 on file Net Income-$65.69M-$65.69MderivedN/M vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenon Pharmaceuticals Inc. · CIK 1582313 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$77,477,000N/M Operating Cash Flowderived-$54,385,000N/M Free Cash Flowderived-$55,168,000N/M ended Dec 31, 2024 · filed Feb 27, 2025 · 58 d after period end